Faron Pharmaceuticals Oy Faron to Present at H.C. Wainwright Conference
September 09 2020 - 6:00AM
RNS Non-Regulatory
TIDMFARN
Faron Pharmaceuticals Oy
09 September 2020
Faron Pharmaceuticals Ltd
("Faron" or the "Company")
Faron Pharmaceuticals to Present at the Virtual H.C. Wainwright
22(nd) Annual Global Investment Conference
TURKU - FINLAND, September 9, 2020 - Faron Pharmaceuticals Ltd (
" Faron") (LON: FARN), the clinical stage biopharmaceutical company
, today announced that Dr. Markku Jalkanen, Chief Executive Officer
of Faron Pharmaceuticals, will present at the virtual H.C.
Wainwright 22(nd) Annual Global Investment Conference on Wednesday,
September 16, 2020 at 11:00 a.m. ET.
To access a live webcast and subsequent archived recording of
the presentation, please visit the "Investors" section on Faron's
website at https://www.faron.com/investors
ENDS
For more information please contact:
Stern Investor Relations, Inc.
Julie Seidel, Naina Zaman
Phone: +(1)212 362 1200
Email: faron@sternir.com
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a clinical stage
biopharmaceutical company developing novel treatments for medical
conditions with significant unmet needs. The Company currently has
a pipeline based on the receptors involved in regulation of immune
response in oncology and organ damage. Clevegen, its precision
immunotherapy, is a novel anti-Clever-1 antibody with the ability
to switch immune suppression to immune activation in various
conditions, with potential across oncology, infectious disease and
vaccine development. Currently in phase I/II clinical development
as a novel macrophage checkpoint immunotherapy for patients with
untreatable solid tumours, Clevegen has potential as a single-agent
therapy or in combination with other standard treatments including
immune checkpoint molecules. Traumakine, the Company's pipeline
candidate to prevent vascular leakage and organ failures, has
completed a phase III clinical trial in Acute Respiratory Distress
Syndrome (ARDS). Plans for its future development are being
finalised to avoid interfering steroid use together with
Traumakine. Faron is based in Turku, Finland. Further information
is available at www.faron.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Private
Policy.
END
NRAKKCBBKBKDCCK
(END) Dow Jones Newswires
September 09, 2020 07:00 ET (11:00 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2023 to Apr 2024